Li Shan
Ueruemqi, 830011, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Current Status of Multidisciplinary Team Consultation for Lung Cancer and Prospects under the Empowerment of Medical Large Models
Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer
Published: July 15, 2026
Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis.
Journal: JTO clinical and research reports
Published: June 02, 2023
NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 31, 2022
Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort.
Journal: Translational lung cancer research
Published: May 16, 2022
Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China.
Journal: Thoracic cancer
Published: August 29, 2021
ELK1 Promotes Epithelial-Mesenchymal Transition and the Progression of Lung Adenocarcinoma by Upregulating B7-H3.
Journal: Oxidative medicine and cellular longevity
Published: July 09, 2021
ACTL6A promotes the growth in non-small cell lung cancer by regulating Hippo/Yap pathway.
Journal: Experimental lung research
Published: April 26, 2021
Identification of Candidate Biomarkers for EGFR-T790M Drug-resistant Gene Mutation in Advanced Lung Adenocarcinoma
Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer
Published: November 18, 2020
A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 31, 2020
Impact of crizotinib on long-term survival of ALK-positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study.
Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Published: July 30, 2019
Last Updated: 09/26/2026